openPR Logo
Press release

Hypoparathyroidism Treatment Market: Advanced Technologies, Growth & Opportunities in Global Industry by 2025

05-03-2017 03:19 PM CET | Health & Medicine

Press release from: Transparency Market Research

Hypoparathyroidism Treatment Market: Advanced Technologies,

Hypoparathyroidism is a conditions when parathyroid glands does not work properly for creation of hormone. Hypoparathyroidism is caused by many reasons as some are like injury or removal of parathyroid glands, DiGeorge syndrome a genetic disorder, autoimmune disease, cancer radiation treatment, and by low magnesium level. The function of parathyroid hormone is to regulate the level of phosphorous and calcium in the blood.

The Symptoms of hypoparathyroidism occurs when the level of calcium is little in blood and the phosphorus is high, due to which the human body show some sign which include muscle spasm, hair loss, dry skin, numbness, and seizures. Hypoparathyroidism occurs in both child and adults. If Hypoparathyroidism occurs in child it show some sign as poor tooth development, vomiting, headaches and mental disorders.

Browse Market Research Report @ http://www.transparencymarketresearch.com/hypoparathyroidism-treatment-market.html

The present of Hypoparathyroidism in the body can be exam various test like PTH blood test, calcium blood test, also by ECG to check abnormal heart rhythm and also by CT scan to exam the deposition of calcium in brain. Hypoparathyroidism are most common problem now a days due to the lifestyle and eating habits.

Hypoparathyroidism treatment market is estimated to be a big market over the forecast periods, as the current population over the globe are suffering from hypoparathyroidism, For instance, a report published by Endocrine Society in 2016, it was 60-8,000 patients in the U.S are suffering from hypoparathyroidism.

Players are coming with new technology advancement for the treatment of hypoparathyroidism, For instance, in January 2015, Shire-NPS Pharmaceuticals, Inc. got approval from a product used for treatment of hypoparathyroidism name as NATPARA (parathyroid hormone) which is an injection for subcutaneous use. Current market are having less players which are working on hypoparathyroidism treatment. All the product in hypoparathyroidism come under pharmaceutical or directly connect to human, so it need to go under some clinical process and have to get the approval from the respective agency before going to commercializes in the market which is a restraints for the segment.

Hypoparathyroidism treatment market have huge potentials for all the players are working or willing to work to come up with new product in this segments. For instance, in first quarter of 2015, Shire has purchased NPS Pharma in $5.2 Billion due to the product name as Natpara an injection used for the treatment of hypoparathyroidism. The population with hypoparathyroidism also show the high interest rate for getting the treatment.

For instance, based on the publication by European Union (EU 28) in June 2016, less the 5 in 10,000 peoples in Europe Union is affected by hypoparathyroidism, which will be equivalent to total of fewer than 257,000 peoples. Many players also in process to make enters with their products into the market, as instance EnteraBio Ltd., is positively received an opinion in Europe market, and also currently focusing in the U.S.

Fill the Form for an Exclusive Sample of this Report @ http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=22715

Geographically, Hypoparathyroidism Treatment Market is segmented into North America, Latin America, Western Europe, Eastern Europe, Asia Pacific, Japan, Middle East and Africa. North America will be the potential market for the players as there is huge demand for the product, and the players are also coming with new product with proper FDA approval. Europe and Asia-Pacific is also a market where the players grow as the potentials.

Some of the players for Hypoparathyroidism Treatment Market are Shire-NPS Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd, EnteraBio Ltd., WCCT GLOBAL INC., Takeda Pharmaceutical Company Limited, Novartis AG, and GlaxoSmithKline plc.

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Contact Us

Transparency Market Research
State Tower,
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Hypoparathyroidism Treatment Market: Advanced Technologies, Growth & Opportunities in Global Industry by 2025 here

News-ID: 522377 • Views: 185

More Releases from Transparency Market Research

Meningitis Diagnostic Testing Market Outlook, Trend, Growth and Share Estimation …
Meningitis Diagnostic Testing Market: Overview The global meningitis diagnostic testing market was valued over US$ 105.5 Mn in 2016 and is projected to register cumulative annual growth rate (CAGR) of over 3.0% from 2017 to 2025, according to a new report published by Transparency Market Research (TMR) titled "Meningitis Diagnostic Testing Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2017-2025". The report suggests that rising demand for innovative
Metformin Hydrochloride API Market to Expand at a CAGR of ~5% from 2021 to 2031
Metformin Hydrochloride API Market: Introduction According to the report, the global metformin hydrochloride API market was valued at ~US$ 300 Mn in 2020 and is projected to expand at a CAGR of ~5% from 2021 to 2031. Metformin hydrochloride is primarily used in the treatment of diabetes. The prevalence of diabetes is expected to increase across the world due to change in lifestyle and factors such as malnutrition and genetic mutations.
Telehealth Market to Reach the Value of US$ 15 Bn by the End of 2028
Telehealth Market: Introduction According to the report, the global telehealth market was valued at US$ 7.8 Bn in 2020 and is projected to expand at a CAGR of 7% from 2021 to 2028. The global telehealth market has witnessed strong growth in the past few years. Telehealth is no longer an option, but a necessity due to the increasing dangers of COVID-19. Read Report Overview - https://www.transparencymarketresearch.com/telehealth-market.html The crisis presents an opportunity
Lyme Disease Treatment Market Growth Trends, Current Demand, and Development Rep …
Lyme Disease Treatment Market: Introduction According to the report, the global Lyme disease treatment market was valued at US$ 1.58 Bn in 2020 and is projected to expand at a CAGR of ~6% from 2021 to 2031. Increase in pet ownership, surge in awareness & adoption of veterinary care, and rise in healthcare expenditure on animals are anticipated to drive the global Lyme disease treatment market from 2021 to 2031.North America

All 5 Releases


More Releases for Hypoparathyroidism

New Drug Development and Government Support to Root Out Hypoparathyroidism
The global hypoparathyroidism treatment landscape that only gained much significance post the FDA approval of Natpara in 2015, is projected grow at a rather robust CAGR of approximately 8% through 2026. As per a recent in-depth analysis by Future Market Insights (FMI), the valuation of global hypoparathyroidism treatment market is expected to stand at US$ 663.7 Million in 2019. Although the growth rate is expected to showcase similar trends, the
Hypoparathyroidism-Pipeline Review H2 2017
ReportsWeb.com has announced the addition of the “Hypoparathyroidism-Pipeline Review H2 2017” this report provides an overview of the Non-Hodgkin Lymphoma-Pipeline landscape.  Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Hypoparathyroidism-Pipeline Review, H2 2017, provides an overview of the Hypoparathyroidism (Hormonal Disorders) pipeline landscape. Hypoparathyroidism is decreased function of the parathyroid glands with underproduction of parathyroid hormone. This leads to low levels of calcium in the blood, often causing cramping and twitching of
Research Delivers Insight into the Global Outlook for Hypoparathyroidism Treatme …
Hypoparathyroidism is a conditions when parathyroid glands does not work properly for creation of hormone. Hypoparathyroidism is caused by many reasons as some are like injury or removal of parathyroid glands, DiGeorge syndrome a genetic disorder, autoimmune disease, cancer radiation treatment, and by low magnesium level. The function of parathyroid hormone is to regulate the level of phosphorous and calcium in the blood. The Symptoms of hypoparathyroidism occurs when the
Hypoparathyroidism Pipeline Market Reviews in H1 2017 Stages, Targets, Routes of …
The Hypoparathyroidism pipeline guide evaluates Hypoparathyroidism (Hormonal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Complete report on http://www.reportsnreports.com/reports/1010771-hypoparathyroidism-pipeline-review-h1-2017.html Main key players of Hypoparathyroidism pipeline are Ascendis Pharma A/S, Chugai Pharmaceutical Co Ltd, Eli Lilly and Company, Entera Bio Ltd, Pharis Biotec GmbH, Shire Plc Hypoparathyroidism is decreased function of the parathyroid glands with underproduction of parathyroid hormone. This leads to
Emerging Trends And Dynamics In The Hypoparathyroidism Treatment Market Through …
Hypoparathyroidism is a conditions when parathyroid glands does not work properly for creation of hormone. Hypoparathyroidism is caused by many reasons as some are like injury or removal of parathyroid glands, DiGeorge syndrome a genetic disorder, autoimmune disease, cancer radiation treatment, and by low magnesium level. The function of parathyroid hormone is to regulate the level of phosphorous and calcium in the blood. The Symptoms of hypoparathyroidism occurs when the
Global Hypoparathyroidism Treatment Market Share by Industry Research 2017 - 202 …
Hypoparathyroidism is a conditions when parathyroid glands does not work properly for creation of hormone. Hypoparathyroidism is caused by many reasons as some are like injury or removal of parathyroid glands, DiGeorge syndrome a genetic disorder, autoimmune disease, cancer radiation treatment, and by low magnesium level. The function of parathyroid hormone is to regulate the level of phosphorous and calcium in the blood. The Symptoms of hypoparathyroidism occurs when the